It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease

The first disease modifying treatments (DMT) of multiple sclerosis (MS) were introduced in the 1990s, and since then numerous new drugs have emerged. Tailoring the treatment in the individual patients with MS is difficult and requires detailed knowledge of the efficacy and risks of all available preparations. Comparing different drugs alone from their effects over placebo or first-generation drugs in the randomised controlled trials is problematic because these studies have been applied to different MS populations, and although there has been a certain harmony in inclusion criteria between such studies, the natural selection of study candidates from the different background MS populations may vary considerably. The many available DMTs enable preparation shifts, typically caused by inefficacy, side effects, adverse events or inconvenience. ‘Real life’ head-to-head observational studies comparing the effects of different DMTs treatments and shifts between them are important and necessary instruments for clinicians and researchers, but such studies…

Read article at journal's website

Related Articles


Your email address will not be published.